A man who recently had a Lu177 treatment and is taking Xgeva and Zytiga has been experiencing severe serum (blood) calcium loss. Why might this be happening, and what should he do?
The only way to make these significant clinical decisions with confidence is to be sure that before assuming that you are castrate resistant your testosterone levels must be confirmed by either mass spectrometry or an immunoassay method that has been validated at low testosterone levels and interpreted with caution before any changes are made to treatment management.
The Food and Drug Administration (FDA) approved apalutamide (ERLEADA), for men with metastatic castration-sensitive prostate cancer (mCSPC).
A preliminary study showed that along with systemic therapies, salvage lymph node dissection (removal) in men with non-metastatic (M0) castration-resistant prostate cancer might delay cancer recurrence.
Results from the PROCEED registry found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). A median survival means that one half of the men who participated in the registry lived longer than four years.
Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
An emerging class of drugs are made up of a radioactive particle that can kill cells attached to a ‘homing device’ to seek out cancers by detecting the presence of a target molecule on their surface.
There are Solutions
One of the possible side effects you might experience after having prostate cancer surgery or radical prostatectomy or RP is incontinence. Incontinence or the unwanted leakage of urine can be just a minor dripping of urine, or it can be the complete and total loss of control of your urine.
The adjuvant group had a significant 74% decreased the risk of biochemical recurrence compared with the observation arm. The 10-year overall survival rates did not differ significantly between the adjuvant and observation groups (92% and 87%, respectively).
According to a press release issued by Astellas and Pfizer that the FDA has granted a priority review to enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.
The study concluded that the adjuvant group had a significant 74% decreased risk of biochemical prostate cancer recurrence compared to men who had only surgery.
Metastatic Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
Prostate Cancer (Copay) now open at Patient Advocate Foundation Co-Pay Relief.
We should note that the two scans performed equally well in men who had their recurrence only in the prostate bed. However, the trial also showed that the PSMA PET scan detected more cancerous pelvic lymph nodes and non-regional metastases.
Research shows that aloe vera alone is ineffective and may worsen skin reactions from radiation treatment. Research has shown that the cleansing the skin daily with mild moisturizing soaps is most beneficial.
Update on the Guidelines for the Prevention and Management of Osteonecrosis of the Jaw
We are happy to announce that on July 30, 2019, the Food and Drug Administration (FDA) approved a new drug, darolutamide (NUBEQA®, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of men with non-metastatic castration-resistant prostate cancer.
In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.
This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response.
There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer. In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
We can conclude that it isn’t necessary for all men taking Zytiga plus prednisone to continue ADT, but some men will see an increase in their testosterone levels, warranting close monitoring and adding back ADT to their treatment.
After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment.